Nucl Med Mol Imaging.
2011 Dec;45(4):299-307.
Systemic Endoradiotherapy with Carrier-Added 4-[131I]Iodo-L-Phenylalanine: Clinical Proof-of-Principle in Refractory Glioma
- Affiliations
-
- 1Department of Nuclear Medicine/PET Centre, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437 Bad Berka, Germany. richard.baum@zentralklinik.de
- 2ABX-CRO Advanced Pharmaceutical Services, Forschungsgesellschaft m.b.H, 01307 Dresden, Germany.
- 3Department of Nuclear Medicine, Laboratory of Radiopharmaceutical Chemistry, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany.
- 4Department of Nuclear Medicine, Experimental Nuclear Medicine and Radiopharmacy, University of Wurzburg, 97080 Wurzburg, Germany.
Abstract
- PURPOSE
To explore feasibility, tolerability, dosimetry and probable efficacy of intravenous endoradiotherapy with carrier-added 4-[131I]iodo-L-phenylalanine (c.a. 131I-IPA) in refractory high-grade glioma.
METHODS
Two male patients (45 and 50 years), with longstanding, extensively pre-treated gliomas and evidence of progression underwent single intravenous injections of 2 and 4 GBq of c.a. 131I-IPA, respectively. Tumour targeting was verified by 131I-IPA single-photon emission computed tomography (SPECT). Metabolic and morphological changes indicative of tumour response were assessed by sequential [18F] fluoroethyltyrosine (18F-FET) positron emission tomography (PET) and contrast-enhanced magnetic resonance imaging (MRI) following therapy. Further monitoring included clinical state, safety laboratory, quality of life and dosimetry. Absorbed mean organ and whole-body doses were determined according to the Medical Internal Radiation Dose (MIRD) scheme using OLINDAEXM based on serial planar scintigraphy.
RESULTS
Both patients tolerated the treatment well. No evidence of acute or delayed organ toxicity was observed. 131I-IPA accumulated in the tumour recurrences identified by MRI/18F-FET. In patient 1, PET showed progressively decreasing maximum standardised uptake values (SUVmax) over 10 months, indicating metabolic response, paralleled by reduced contrast enhancement and tumour volume on MRI. Progression occurred 18 months after therapy. Treatment was repeated using 6.6 GBq of 131I-IPA, to which no response was observed. Patient 2, followed-up for 3 months after therapy, showed stable disease on MRI and PET. Mean absorbed whole body doses ranged from 0.13 to 0.17 mSv/MBq, with the highest absorbed organ doses to kidneys, bladder and heart (0.86-1.23; 0.49-0.6 and 0.45-0.56 mSv/MBq).
CONCLUSION
Systemic endoradiotherapy using up to 6.6 GBq of c.a.131I-IPA is not associated with clinically detectable toxicity. Measurable anti-tumour effects in gliomas were observed. 131I-IPA warrants further evaluation as glioma therapy.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Biodistribution of 3-<131I>iodo-O-mythyl-L-alpha-methyltyrosine in Tumor Bearing Rats: A Comparison Study with L-3-<131I>iodo-alpha-methyltyrosine
- The Effect of Cycolooxygenase (COX-1 and COX-2) on the Bacterial Toxin Formyl Methionyl Leucyl Phenylalanine (fMLP) Induced Contraction of the Rabbit Bladder Muscle
- Fungal and Plant Phenylalanine Ammonia-lyase
- Effect of Carrier on Labeling and Biodistribution of Re-188-Hydroxyethylidene diphosphonate
- The Effects on the MSG with Phenylalanine Treatment in the Area Postrema of the Rat Medulla
